title: Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
authors.affiliation: Department of Immunology, The Canberra Hospital, Canberra, Australia; The Australian National University Medical School, Australian National University, Canberra, Australia. Electronic address: Elizabeth.daSilva@act.gov.au.
authors.forename: Elizabeth Nicole
authors.initials: EN
authors.lastname: da Silva
authors.affiliation: Department of Immunology, The Canberra Hospital, Canberra, Australia; The Australian National University Medical School, Australian National University, Canberra, Australia.
authors.forename: Katrina Louise
authors.initials: KL
authors.lastname: Randall
mesh_terms: D000707:Anaphylaxis / Q000517:prevention & control*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001514:Bee Venoms / Q000009:adverse effects*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007299:Insect Bites and Stings / Q000188:drug therapy; D008297:Male; D008415:Mastocytosis / Q000628:therapy*; D008875:Middle Aged; D000069444:Omalizumab
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D001514:Bee Venoms; D000069444:Omalizumab